Search

Skip to main content Evaluation of Indeterminate Liver Lesions (LR-3 and LR-4) The Liver Imaging Reporting and Data System (LI-RADS) standardizes imaging interpretation for liver lesions. Our group has a particular interest in indeterminate liver lesions (LI-RADS-3 and LR-4), which present challenges…

The Drapkin Lab investigates the molecular drivers of oncogenesis, metastasis, and chemoresistance in small cell lung cancer (SCLC) to discover new therapeutic targets. 

Skip to main content Health Care Delivery Research Efficient delivery of proven health care interventions plays a critical role in outcomes for patients at-risk and with HCC. We have shown that delays in diagnosis and treatment, fragmentation of care, and disparities in access can significantly impac…

Learn about the Rothermel Lab's research.

The Bann Laboratory focuses on discovering novel mechanistic targets to treat heart failure. We aim to identify regulators of cardiac cell fate reprogramming and regeneration as a molecular strategy to repair and heal the heart following injury.

Meet the Rothermel Lab team.

Skip to main content Cost Effectiveness of HCC screening We have conducted cost-effectiveness studies showing that screening is cost-effective compared to no screening. We have also shown that biomarker-based screening would be cost-effective, depending on utilization, costs of tests, and sensitivity…

Contact the Rothermel Lab.

Meet the Sun Lab team.

Skip to main content Effectiveness of Ultrasound and AFP for HCC Screening Ultrasound and alpha-fetoprotein (AFP) have long been cornerstones of hepatocellular carcinoma (HCC) screening in patients with cirrhosis. We have explored how ultrasound quality, operator variability, and patient characterist…